Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beta Bionics (BBNX) Gross Margin (2024 - 2026)

Beta Bionics' Gross Margin history spans 3 years, with the latest figure at 59.5% for Q1 2026.

  • On a quarterly basis, Gross Margin rose 864.0% to 59.5% in Q1 2026 year-over-year; TTM through Mar 2026 was 57.15%, a 322.0% increase, with the full-year FY2025 number at 55.4%, up 29.0% from a year prior.
  • Gross Margin hit 59.5% in Q1 2026 for Beta Bionics, up from 58.98% in the prior quarter.
  • Over the last five years, Gross Margin for BBNX hit a ceiling of 59.5% in Q1 2026 and a floor of 50.86% in Q1 2025.
  • Historically, Gross Margin has averaged 55.4% across 3 years, with a median of 55.48% in 2025.
  • Biggest five-year swings in Gross Margin: plummeted -482bps in 2025 and later surged 864bps in 2026.
  • Tracing BBNX's Gross Margin over 3 years: stood at 57.19% in 2024, then grew by 3bps to 58.98% in 2025, then grew by 1bps to 59.5% in 2026.
  • Business Quant data shows Gross Margin for BBNX at 59.5% in Q1 2026, 58.98% in Q4 2025, and 55.48% in Q3 2025.